Treatments and Procedures Archives | Page 7 of 7

How Do Cancer Drugs Block Pathways?

by Richard Saltus

Cells are like young children – they need a lot of guidance on how to behave. Your body’s cells are constantly getting that help – in the form of hormones, growth factors, and other chemicals telling them when to rest, grow, duplicate their DNA, divide, or even self-destruct.

These commands are relayed from the cell’s surface to its nucleus by molecular pathways, also called signaling pathways, which are a series of interacting proteins that relay cellular messages, much as cell phone towers relay phone calls. When the commands reach the cell nucleus, they activate or turn off genes to determine how the cell responds.

Can Breast Cancer Patients Avoid Multiple Surgeries?

by Dana-Farber Staff

When Jane Davis was diagnosed with breast cancer last July, she began learning as much as she could about her disease. Davis quickly discovered one of the most startling statistics about breast cancer: Up to 40 percent of women who have a lumpectomy require a second surgery. That’s because surgeons often cannot microscopically remove the entire tumor.

But Mehra Golshan, MD, FACS, director of Breast Surgical Services at Dana-Farber/Brigham and Women’s Cancer Center, is trying to change that with a phase I breast surgery pilot study. It’s the first of its kind in the world.

Proton Therapy No Better Than Traditional Therapy for Prostate Cancer Patients

by Dana-Farber

This post was originally published in December 2012.

When it comes to treating prostate cancer, proton radiotherapy (PRT) is no better than traditional intensity-modulated radiation therapy (IMRT), according to a new study reported in the Journal of the National Cancer Institute on Friday.

PRT is an advanced but expensive treatment option for some prostate cancer patients. However, the researchers found that the therapy offers no added treatment benefit than the standard therapy. The article concluded: “Although PRT is substantially more costly than IMRT, there was no difference in toxicity in a comprehensive cohort of Medicare beneficiaries with prostate cancer at 12 months post-treatment.”

Breast Cancer, Aromatase Inhibitors, and Bone Density

by Dana-Farber Staff

Aromatase inhibitors (AIs), such as Arimidex, Aromasin, and Femara, have proven to be more effective than previous hormonal treatments for treating both early and advanced breast cancer in post-menopausal women whose tumors are dependent on estrogen. Compared with tamoxifen, these drugs are less likely to cause blood clots or raise the risk of endometrial cancer. As a result, AIs are used both in patients with early breast cancer and in those with metastatic disease.

Treating Eye Cancer Directly

by Dana-Farber Staff

For years, researchers have sought an avenue to deliver chemotherapy directly to retinoblastoma tumors – cancers of the retina of the eye, which primarily affect children under age 5. It turns out that the body itself offers just such a route.

Can aspirin prevent or treat cancer?

by Dana-Farber

Aspirin has been around for over 100 years. In the last 50 years, research has shown that regular use of aspirin may prevent heart disease. Now a new study points to aspirin’s effectiveness in preventing and treating cancer.

A recent University of Oxford investigation pooled more than 50 studies to show that regular aspirin use could reduce your chances of developing certain types of cancer, and may be effective in treating some cancers as well. We talked to Charles S. Fuchs, MD, MPH, director of the Gastrointestinal Cancer Center at Dana-Farber for his take on the recent research.

Five reasons to be optimistic about the future of cancer treatment

by Dana-Farber

It’s not always easy to recognize that we live in a golden age. Too often we fail to appreciate the amazing things going on around us because we‘re so caught up in day-to-day activities and pressing demands that we presume that the extraordinary is rather ordinary.

So it may be with cancer treatment in 2012. And the future looks to be even better – not necessarily easier, simpler, or cheaper, but unequivocally better.

Here are five reasons why.

New developments in brain tumor treatment: Five questions for David Reardon, MD

by DFCI Staff

More than 600,000 people in the United States are living with a primary brain tumor — one that begins and stays in the brain — and over 60,000 adults and children will be diagnosed with a brain tumor this year.

In recognition of May as Brain Tumor Awareness Month, we asked David Reardon, MD, clinical director of the Center for Neuro-Oncology at Dana-Farber/Brigham and Women’s Cancer Center, for the latest advances in brain tumor research and patient care.

From old drugs, new cancer treatments

by DFCI Staff

When it comes to finding better drugs for cancer, Dana-Farber oncologist Dr. David Frank is not a patient man. While new cancer science promises to bring novel, improved therapies to the bedside, it can take many years — and Frank isn’t willing to wait.

“We need to get new treatments to patients as soon as possible,” he says.

Treating childhood cancer worldwide

by Dana-Farber Staff

On International Childhood Cancer Day, it’s important to remember that global support, research, and treatment are vital to ensuring that children in developing countries have the same chance at survival as their peers in the U.S. Physicians such as Dr. Leslie Lehmann from Dana-Farber/Boston Children’s Cancer and Blood Disorders Center travel all over the world to deliver expert, curative care to young patients with cancer. Here is her story.

Rwanda is a tiny country in central Africa with much beauty but few resources. The genocide in 1994 that killed nearly a million people also devastated the health care system. Many people do not receive basic health care services and cancer care was nonexistent. It was impossible to even tell how common cancer was – people would die from a mass, or from bleeding, or infection without ever having a diagnosis.

The country has over 11 million people with not a single physician trained in caring for people with cancer. It’s a very sad situation.

This is beginning to change a bit. Through the Partners in Health (PIH) organization, I became part of a U.S.– Rwandan team led by Sara Stulac, PIH’s director of pediatrics, assembled at the Rwinkwavu hospital with the goal of providing consistent quality care to children with cancer. Sara had lived in Rwanda working at this rural PIH-sponsored hospital for six years. I went to Rwanda with Kathleen Houlahan, a pediatric oncology nurse and nurse director of the Jimmy Fund Clinic at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and Dr. Larry Shulman, medical oncologist and chief medical officer of Dana-Farber, who is Senior Oncology Adviser for PIH and leads Dana-Farber/Brigham and Women’s Cancer Center efforts in Rwanda.